November 1992
Volume 33, Issue 12
Free
Articles  |   November 1992
Subconjunctival sustained release 5-fluorouracil.
Author Affiliations
  • D L Blandford
    Department of Ophthalmology, University of Kentucky, Lexington.
  • T J Smith
    Department of Ophthalmology, University of Kentucky, Lexington.
  • J D Brown
    Department of Ophthalmology, University of Kentucky, Lexington.
  • P A Pearson
    Department of Ophthalmology, University of Kentucky, Lexington.
  • P Ashton
    Department of Ophthalmology, University of Kentucky, Lexington.
Investigative Ophthalmology & Visual Science November 1992, Vol.33, 3430-3435. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      D L Blandford, T J Smith, J D Brown, P A Pearson, P Ashton; Subconjunctival sustained release 5-fluorouracil.. Invest. Ophthalmol. Vis. Sci. 1992;33(12):3430-3435.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The authors have developed a sustained release device for 5-fluorouracil (5-FU) made up of a 12 mg pellet of drug coated in a mixture of permeable and impermeable polymers. When implanted subconjunctivally in rabbits, these devices released 5-FU at approximately 1 mg/d for over 10 days. Devices were implanted into four cynomolgus monkey eyes after posterior lip sclerotomy. One eye (treatment) received a device that contained 12 mg 5-FU and the other eye (control) received a placebo device that contained no drug. In control eyes, intraocular pressures returned to normal within 1 wk. In treatment eyes, pressures remained significantly lower throughout the experimental period (3 mo). There was no indication of impaired wound healing, corneal toxicity, inflammation, or damage to the ciliary body in rabbits or monkeys.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×